Sen. Burr’s Parting Gifts For US FDA Include ‘Platform’ Pathway
Executive Summary
The year-end package of US FDA reforms reflects the impact of one now-retired US Senator: North Carolina’s Richard Burr’s objections helped take out a number of ‘anti-innovation’ provisions – while still securing inclusion of a ‘Platform Technologies’ pathway that might otherwise not have been enacted.
You may also be interested in...
Drug Makers Look To Simplify Application Process With New ICH Guidance On Platform Methods
As ICH member countries prepare to implement Q2(R1)/Q14 guidelines, industry is focusing on provisions in both for platform analytical procedures, which applicants for drug approvals and biologics licenses could use to reduce method validation requirements. Pfizer undertook the first commercial application of the platform analytical approach, which is widely used in development.
US FDA Guidance ‘Best Practices’: How Much Room For Improvement?
Outlining ideas to improve the efficiency of its guidance development policy fulfills a legislative mandate, but US FDA also wants credit for the strides it has already taken.
Can The US FDA Do More To Help Advance Rare Disease Therapies?
The National Academy of Medicine is launching a Congressionally mandated study of the US FDA’s regulatory approach to rare disease treatments. The first question is whether there is anything more that FDA can do.